PDE4A and idiopathic pulmonary fibrosis: As recently reviewed by Claire Lugnier, PDE4 inhibition has many possible downstream pathways, leading to reduced inflammation, reduced oxidative stress, TNF-α, and cytokine production [42], which are all relevant for IPF progression.